50 Big Debates in Gynecologic Oncology - Title page

pp iii-iii

Copyright page

pp iv-iv

Contents

pp v-xii

Contributors

pp xiii-xxiv

Section I - Perioperative Management

pp 1-10

Debate 1A - Should Routine Mechanical Bowel Preparation be Performed before Primary Debulking Surgery?

pp 1-3

Debate 1B - Should Routine Mechanical Bowel Preparation be Performed before Primary Debulking Surgery?

pp 4-5

Debate 2A - Should Preoperative Carbohydrate Loading be Routine prior to Debulking Surgery?

pp 6-8

Debate 2B - Should Preoperative Carbohydrate Loading be Routine prior to Debulking Surgery?

pp 9-10

Section II - Screening, Prevention, and Early Diagnosis

pp 11-22

Debate 3A - Should Women with BRCA Mutations be Offered Bilateral Salpingectomy with Delayed Oophorectomy for Ovarian Cancer Risk Reduction?

pp 11-12

Chapter 3B - Should Women with BRCA Mutations be Offered Bilateral Salpingectomy with Delayed Oophorectomy for Ovarian Cancer Risk Reduction?

pp 13-15

Debate 4A - Can High-risk HPV Testing be Used Alone as the Primary Screening Modality for Cervical Cancer?

pp 16-19

Debate 4B - Can High-risk HPV Testing be Used Alone as the Primary Screening Modality for Cervical Cancer?

pp 20-22

Section III - Ovarian Cancer

pp 23-164

Debate 5A - Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?

pp 23-25

Debate 5B - Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?

pp 26-28

Chapter 6A - In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Profiling be Routinely Done to Guide Adjuvant Therapy?

pp 29-31

Debate 6B - In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Profiling be Routinely Done to Guide Adjuvant Therapy?

pp 32-34

Debate 7A - Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse?

pp 35-37

Debate 7B - Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse?

pp 38-40

Debate 8A - Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?

pp 41-43

Debate 8B - Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?

pp 44-46

Debate 9A - How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage I Epithelial Ovarian Cancer?

pp 47-48

Debate 9B - How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage I Epithelial Ovarian Cancer?

pp 49-51

Debate 10A - Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treated with Neoadjuvant Chemotherapy?

pp 52-54

Debate 10B - Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treated with Neoadjuvant Chemotherapy?

pp 55-57

Debate 11A - Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced Ovarian Cancer prior to Treatment with Adjuvant Chemotherapy?

pp 58-60

Debate 11B - Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced Ovarian Cancer prior to Treatment with Adjuvant Chemotherapy?

pp 61-63